Impact of genomics on drug discovery and clinical medicine

QJM: An International Journal of Medicine

Volumn 93, Issue 7, 2000, Pages 391-423

  Emilien, G ^a,d   Ponchon, M ^a   Caldas, C ^b   Isacson, O ^c   Maloteaux, J M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ASTEMIZOLE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHEMOKINE; CISAPRIDE; GLUCOCORTICOID; MERCAPTOPURINE; MEXILETINE; NEUROLEPTIC AGENT; OMEPRAZOLE; OPIATE; SALBUTAMOL; SULFONAMIDE; TERFENADINE; TIOGUANINE; TRICYCLIC ANTIDEPRESSANT AGENT; VASCULOTROPIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL MEDICINE; CLINICAL RESEARCH; DIABETES MELLITUS; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG METABOLISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ENDOCRINOLOGY; ETHICS; GENE EXPRESSION; GENE SEQUENCE; GENE TECHNOLOGY; GENE THERAPY; GENETICS; HUMAN; HUNTINGTON CHOREA; MIGRAINE; NEUROPSYCHIATRY; NONHUMAN; OBESITY; ONCOLOGY; OUTCOMES RESEARCH; PARKINSON DISEASE; PATHOGENESIS; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 0033928586     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/93.7.391     Document Type: Review

References (255)

1. Yao SN, Wilson JM, Nabel EG, Kurachi S, Hachiya HL, Kurachi K. Expression of human factor IX in rat capillary endothelial cells: Toward somatic gene therapy for hemophilia B. Proc Natl Acad Sci USA 1991; 88:8101-5.
2. Shine J, Seeburg PH, Martial JA, Baxter JD, Goodman HM. Construction and analysis of recombinant DNA for human chorionic somatomammotropin. Nature 1977; 270:494-9.
3. Bassett DE Jr, Boguski MS, Spencer F, Reeves R, Kim S, Weaver T, Hieter P. Genome cross-referencing and XREFdb: Implications for the identification an analysis of genes mutated in human disease. Nature Genet 1997; 15:339-43.
4. McKusick VA. Genomics: structural and functional studies of genomes. Genomics 1997; 45(2):244-9.
5. Lander ES, Schork N. Genetic dissection of complex traits. Science 1994; 265:2045-97.
6. Marshall A. Laying the foundations for personalized medicines. Nature Biotech 1997; 15(10):954-7.
7. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinetics 1995; 29:192-209.
8. Relling MV, Lin J-S, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Therapeut 1992; 52:643-58.
9. Ratain MJ, Mick R, Janisch L, Berezin F, Schilsky RL, Vogelzang NJ, Kut M. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics 1996; 6(1):93-101.
10. Pratt CM, Ruberg S, Morganroth J, et al. Dose-response relation between terfenadine (Seldane) and the QT interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 1996; 131:472-80.
11. Woosley RL. Cardiac actions of antihistamines. Ann Rev Pharmacol Toxicol 1996; 36:233-52.
12. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335:290-1.
13. Aithal CP, Day CP, Kesteven PJL, Daly AK. Association of the polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353:717-19.
14. Spielberg SP. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinetics Biopharmaceutics 1996; 24:509-19.
15. Hickman D, Sim E. N-Acetyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem Pharmacol 1991; 42:1007-14.
16. Grant DM. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 1993; 3:45-50.
17. Vatsis KP, Martel KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA 1991; 88:6333-7.
18. Cascorbi J, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotype activity. Am J Hum Genet 1995; 57:581-92.
19. Gawronska-Szklarz B, Gornik W, Pawlik A, Kunicki P, Wojcicki J, Sitkiewicz D, et al. N-Acetylation and hydroxylation polymorphism in type II diabetics with microvascular disturbances. Eur J Clin Pharmacol 1997; 51:431-6.
20. Evans DAP. N-Acetyltransferase. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992:95-178.
21. Roots I, Drakoulis N, Brockmöller J. Polymorphic enzymes and cancer risk: Concepts, methodology and data review. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York, Pergamon Press, 1992:815-41.
22. Patkowski J, Malolepszy J, Milejski P, Orzecchowska-Juzwenko K, Nittner-Marszalska M. Acetylation phenotype in the atopic allergy. Pol Tyg Lek 1987; 42:870-3.
23. Gawronska-Szklarz B, Luszawska-Kutrzeba T, Czaja-Bulsa G and Kurzawski G. Relationship between acetylation polymorphism and risk of atopic diseases. Clin Pharmacol Ther 1999; 65:562-9.
24. Meyer UA. Medically relevant genetic variation of drug effects. Evolution in Health and Disease. Oxford, Oxford University Press, 1997.
25. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129:1027-30.
26. Furuta T, Ohashi K, Kosuge K, Zhao X-J, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65:52-61.
27. Jurima-Romet M, Foster BC, Casley WL, Rode A, Vloshinsky P, Huang HS, Geertsen S. CYP2D6-related oxidation polymorphism in a Canadian lnuit population. Canad J Physiol Pharmacol 1997; 75:165-72.
28. Spina E, Gitto C, Avenoso A, Campo CM, Caputi AP, Perucca E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 1997; 51:395-8.
29. Hamelin BA, Turgeon J, Vallee F, Belanger PM, Paquet F, Lebel M. The disposition of fluoxetine but not sertraline is altered in poor metabolisers of debrisoquine. Clin Pharmacol Therapeutics 1996; 60:512-21.
30. Lin K-M. Psychopharmacology in cross-cultural psychiatry. The Mount Sinai Journal of Medicine 1996; 63:283-4.
31. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51:289-95.
32. Tyndale R, Sunahara R, Inaba T, Kalow W, Gonzalez F, Niznik H. Neuronal cytochrome P450IID1 (debrisoquine/ sparteine type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 1991; 40:63-8.
33. Llerena A, Edman G, Cobaleda I, Benitez J, Schalling D, Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity: suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 1993; 87:493-503.
34. Deininger M, Szumlanski CL, Otterness DM, Van Loon J, Ferber W, Weinshilboum RM. Purine substrates for human thiopurine methyltransferase. Biochem Pharmacol 1994; 48:2135-8.
35. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6:279-90.
36. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994; 343:1188-90.
37. Schutz E, Gummert J, Mohr F, Oellerich M. Azathiopurine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993; 341:436.
38. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, Spurr N, Lennard L, Wieben E, Weinshilboum R. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15:17-30.
39. Otterness D, Szumlanski C, Lennard L, Kleletsdal B, Aarbakke J, Park-Hah JO, Iven H, Schmiegelow K, Branum E, O'Brien J, Weinshilboum R. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62:60-73.
40. Lum A, Le Marchand L. A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. Cancer Epidemiol Biomarkers Prevent 1998; 7:719-24.
41. 2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999; 65:519.
42. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, Sham P, Kerwin R. Association between clozapine response and allelic variation in 5-HT(2A) receptor gene. Lancet 1995; 346:281-2.
43. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Cilfix BM, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995; 92:12260-4.
44. Abbott CW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SAN. MiRP1 forms I(Kr) potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999; 97:175-87.
45. Hall IP, Wheatley A, Wilding P, Liggett SB. Association of Glu27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic. Lancet 1995; 345:1213-14.
46. Tan S, Hall IP, Dewar J, Dow E, Lipworth B. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitization in moderately severe asthmatics. Lancet 1997; 350:995-9.
47. 2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J 1998; 11:589-93.
48. 2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. J Allergy Clin Immunol 1998; 101:337-41.
49. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33:9414-19.
50. 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am I Respir Cell Mol Biol 1995; 13:25-33.
51. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100:3184-8.
52. Fraefel C, Jacoby DR, Lage C, Hilderbrand H, Chou JY, Alt FW, Breakefield XO, Majzoub JA. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Mol Med 1997; 3:813-25.
53. Howell JM. Is there a future for gene therapy? Neuromuscul Disord 1999; 9:102-7.
54. Jaffe A, Bush A, Geddes DM, Alton EW. Prospects for gene therapy in cystic fibrosis. Arch Dis Child 1999; 80:286-9.
55. Schumacher JM, Short MP, Hyman BT,. Breakefield XO, Isacson O. Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids. Neuroscience 1991;45:561-70.
56. Miao CH, Snyder RO, Schowalter DB, Patijn GA, Donahue B, Winther B, Kay MA. The kinetics of rAAV integration in the liver. Nature Genet 1998; 19:13-15.
57. Song S, Morgan M, Ellis T, Poirier A, Chesnut K, Wang J, et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 1998; 95:14384-8.
58. Leone P, Janson CG, McPhee SJ, During MJ, Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease. Curr Opin Mol Ther 1999; 1:487-92.
59. Long Z, Li L-P, Grooms T, Lockey C, Nader K, Mychkovsky I, Mueller S, Burimski I, Ryan P, Kikuchi G, Ennist D, Marcus S, Otto E, McGarrity G. Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells. Hum Gene Ther 1998; 9:1165-72.
60. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial results after four years. Science 1995; 270:474-80.
61. Marcel T, Crausz DJ. The TMC world-wide gene therapy enrolment report, end 1996. Hum Gene Ther 1997; 8:775-800.
62. Henry TD. Therapeutic angiogenesis. Br Med J 1999; 319:1536-9.
63. Masters CL, Beyreuther K. Science, medicine and the future: Alzheimer's disease. Br Med J 1998; 316:446-8.
64. Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Natural Medicines 1998; 4:607-9.
65. Hubbard R, Lewontin RC. Pitfalls of genetic testing. N Engl J Med 1996; 334:1992-3.
66. Strober M, Morrell W, Burroughs J, Lampert C, Danforth H, Freeman R. A family study of bipolar I disorder in adolescence. Early onset of symptoms linked to increased familial loading and lithium resistance. J Affect Disord 1988; 15:255-68.
67. Weissman MM, Gershon ES, Kidd KK, Prusoff BA, Leckman JF, Dibble E, Hamovit J, Thompson WD, Pauls DL, Guroff JJ. Psychiatric disorders in the relatives of probands with affective disorders. The Yale University-National Institute of Mental Health Collaborative Study. Arch Gen Psychiat 1984; 41:13-21.
68. Pauls DL, Alsobrook JP 2nd, Goodman W, Rasmussen S, Leckman JF. A family study of obsessive-compulsive disorder. Am J Psychiat 1995; 152:76-84.
69. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K, Sieghart W, Aschauer HN, Kasper S. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophrenia Res 1998; 32:101-6.
70. Peroutka SJ, Wilhoit T, Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) Ncol alleles. Neurology 1997; 49:201-6.
71. Thomsen LL, Olesen J, Rusell MB. Familial hemiplegic migraine. Ugeskrift for Laeger 1998; 160:5325-9.
72. Ackerman MJ, Clapham DE. Ion channels-basic science and clinical disease. N Engl J Med 1997; 336:1575-86.
73. Bulman DE. Phenotypic variation and newcomers in ion channel disorders. Hum Mol Genet 1997; 6:1979-85.
74. Hanna MG, Wood NW, Kullmann DM. Ion channels and neurological disease: DNA based diagnosis is now possible, and ion channels may be important in common paroxysmal disorders. J Neurol Neurosurg Psychiat 1998; 65:427-31.
75. Browne DL, Brunt ER, Griggs RC, Nutt JG, Gancher ST, Smith EA, et al. Identification of two new KCNA1 mutations in episodic ataxia/myokymia families. Hum Mol Genet 1995; 4:1671-2.
76. Lehmann-Horn F, Rudel R. Molecular pathophysiology of voltage-gated ion channels. Rev Physiol Biochem Pharmacol 1996; 128:195-268.
77. Ptacek LJ, George AL, Griggs RC, et al. Identification of a mutation in the gene causing hyperkalaemic periodic paralysis. Cell 1991; 67:1021-7.
78. Hogan K. To fire the strain: a second malignant hyperthermia gene. Am J Hum Genet 1997; 60:11303-8.
79. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1 A-voltage-dependent calcium channel. Nature Genet 1997; 15:62-9.
80. Terwindt GM, Ophoff RA, Haan J, et al. Variable clinical expression of mutations in the P/Q-type calcium channel gene in familial hemiplegic migraine. Dutch Migraine Genetics Research Group. Neurology 1998; 50:1105-10.
81. Neufeld NY, Nisipeanu P, Chistik V, et al. The eletroencephalogram in acetozolamide responsive periodic ataxia. Mov Disord 1996; 11:283-8.
82. Shiang R, Ryan SG, Zhu YZ, Hahn AF, O'Connell P, Wasmuth JJ. Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperrekplexia. Nature Genet 1993; 5:351-8.
83. Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Scheffer IE, et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nature Genet 1995; 11:201-3.
84. Auburger G, Ratzlaff T, Lunkes A, Nelles HW, Leube B, Binkofski F, et al. A gene for autosomal dominant paroxysmal choreoathetosis/spasticity (CSE) maps to the vicinity of a potassium channel gene cluster on chromosome 1 p, probably within 2 cM between D1S443 and D1S197. Genomics 1996; 31:90-4.
85. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72:971-83.
86. Albin RL, Tagle DA. Genetics and molecular biology of Huntington's disease. TINS 1995; 18:11-14.
87. Li SH, Schilling G, Young WSI, Li XJ, Margolis RL, Stine OC, Wagster MV, Abbott MH, Franz ML, Ranen NG, Folstein SE, Hedreen JC, Ross CA. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 1993; 11:985-93.
88. Koide R, Ikeuchi T, Onodera O, Tanaka H, Igarashi S, Endo K, Takahashi H, Kondo R, Ishikawa A, Hayashi T, Saito M, Tomoda A, Miike T, Naito H, Ikuta F, Tsuji S. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nature Genet 1994; 6:9-13.
89. Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Garnier JM, Weber C, Mandel JL, Cancel G, Abbas N, Durr A, Didierjean O, Stevanin G, Agid Y, Brice A. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nature Genet 1996; 14:285-91.
90. David G, Abbas N, Stevanin G, Durr A, Yvert G, Cancel G, Weber C, Imbert G, Saudou F, Antoniou E, Drabkin H, Gemmill R, Giunti P, Benomar A, Wood N, Ruberg M, Agid Y, Mandel J-L, Brice A. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nature Genet 1997; 17:65-70.
91. Warren ST. The expanding world of trinucleotide repeats. Science 1996; 271:1374-5.
92. Zoghbi HY. The expanding world of ataxins. Nature Genet 1996; 14:237-8.
93. Reddy PS, Housman DE. The complex pathology of trinucleotide repeats. Curr Opin Cell Biol 1997; 9:364-72.
94. Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? TINS 1993; 16:125-31.
95. Simpson JR, Isacson O. Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum. Exp Neurol 1993; 121:57-64.
96. Rossi JJ. Therapeutic antisense and ribozymes. Br Med Bull 1995; 51:217-25.
97. Haque N, Isacson O. Antisense gene therapy for neurodegenerative disease? Exp Neurol 1997; 144:139-46.
98. Emerich DF, Winn SR, Hantraye PM, Peschanski M, Chen EY, Chu Y, McDermott P, Baetge EE, Kordower JH. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 1997; 386:395-9.
99. Pavia J, de Ceballos ME, Sanchez de la Cuesta F. Alzheimer's disease: relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins. Fundament Clin Pharmacol 1998; 12:473-81.
100. Goate AM, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349:704-6.
101. Sherrington R, Rogaev El, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early onset familial Alzheimer's disease. Nature 1995; 375:754-60.
102. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995; 376:775-8.
103. 1-antichymotrypsin) with Alzheimer's disease. Ann Neurol 1998; 44:387-90.
104. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261:921-3.
105. rd International Springfield Symposium on Advances in Alzheimer Therapy. Springfield IL, 13-15 May 1994.
106. McConnell LM, Koenig BA, Greely HT, Raffin TA. The Alzheimer disease working group of the Stanford program in genomics, ethics and society. Genetic testing and Alzheimer disease: Has the time come? Nature Med 1998; 4:757-9.
107. Kromer LF, Cornbrooks CJ. Identification of trophic factors and transplanted cellular environments that promote CNS axonal regeneration. Ann NY Acad Sci 1987; 495:207-24.
108. Fisher LJ, Jinnah HA, Kale LC, Higgins GA, Gage FH. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-Dopa. Neuron 1991; 6:371-80.
109. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al. Mutations in CU/Zn dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362:59-62.
110. Fridovich I. Superoxide radical and superoxide dismutases. Ann Rev Biochem 1995; 64:97-112.
111. Kunst CB, Mezey E, Brownstein MJ, Patterson D. Mutations in SOD1 associated with amyotrophic lateral sclerosis cause novel protein interactions. Nature Genet 1997; 15:91.
112. Williamson T and Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nature Neurosci 1999; 2:50-6.
113. Van Q, Matheson C, Lopez OT. In vivo neurotrophic effects of CDNF on neonatal and adult facial motor neurons. Nature 1995; 373:341-4.
114. Sagot Y, Tan SA, Baetge EE, Schmalbruch H, Kato AC, Aebischer P. Polymer encapsulated cell lines genetically engineered to release CNTF and slow down progressive motor neuronpathy in the mouse. Eur J Neurosci 1995; 7:1313-22.
115. Aebischer P, Schluep M, Déglon N, Joseph JM, Hirt L, Heyd B, Goddard M, Hammang JP, Zurn AD, Kato AC, Regli F, Baetge EE. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nature Med 1996; 2:696-8.
116. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW. Parkinson disease in twins. An etiology study. JAMA 1999; 281:341-6.
117. Bandmann O, Vaughan J, Holmans P, Marsden CD, Wood NW. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease, Lancet 1997; 350:1136-9.
118. Vieregge P, Schiffke KA, Friedrich HJ, Müller B, Ludin HP. Parkinson's disease in twins. Neurology 1992; 42:1453-61.
119. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983; 33:815-24.
120. Bjorklund A, Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 1979; 177:555-60.
121. Bjorklund A. Cell transplantation and gene therapy in Parkinson disease. Nordisk Medicin 1996; 111(7):225-9.
122. Strecker RE, Sharp T, Brundin P, Zetterstrom T, Ungerstedt U, Bjorklund A. Autoregulation of dopamine release and metabolism by intrastriatal nigral grafts as revealed by intracerebral dialysis. Neuroscience 1987; 22(1):169-78.
123. Isacson O, Deacon T. Neural transplantation studies reveal the brain's capacity for continuous reconstruction. Trends Neurasci 1997; 20:477-82.
124. Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Wells TH, Barrett JN, Graton ST, Mazziotta JC, Eidelberg D, Rottenberg DA. Therapeutic effects of human fetal dopamine cells transplanted in a patient with Parkinson's disease. Prog Brain Res 1990; 82:715-21.
125. Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, Marsden CD, Bjorklund A. Grafts of fetal dopamine neurons survive and improve motor function in parkinson's disease. Science 1990; 247:574-7.
126. Isacson O, Breakefield XO. Benefits and risks of hosting animal cells in the human brain. Nature Med 1997; 3:964-9.
127. Isacson O. The Neurobiology and Neurogenetics of stem cells. Brain Pathol 1999; 9:495-8.
128. Lundberg C, Horellou P, Mallet J, Bjorklund A. Generation of dopa-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene - in vitro characterization and in vitro effects in the rat parkinson model. Exp Neurol 1996; 139:39-53.
129. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8.
130. Frim DM, Yee WM, Isacson O. NGF reduces striatal excitotoxic neuronal loss without affecting concurrent neuronal stress. Neuroreport 1993; 4:655-8.
131. Hagg T, Varon S. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc Natl Acad Sd USA 1993; 90:6315-19.
132. Altar CA, Boylan CB, Jackson C, Hershenson J, Miller J, Wiegand SJ, Lindsay RM, Hyman C. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc Natl Acad Sci USA 1992; 89:11347-51.
133. Wilson JM, Birinyi LK, Salomon RN, Libby P, Callow AD, Mulligan RC. Implantation of vascular grafts lined with genetically modified endothelial cells. Science 1989; 244:1344-6.
134. Zareba W, Moss AJ, Schwartz P, Vincent MC, Robinson JL, Priori SG, Benhorin J, Locati EH, Towbin JA, Keating MT, Lehmann MH, Hall J. Influence of the genotype on the clinical course of the long-QT syndrome. N Engl J Med 1998; 339:960-5.
135. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome. Clinical impact. Circulation 1999; 99:529-33.
136. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 as well as LQT3 models of the long-QT syndrome. Circulation 1997; 96:2038-47.
137. + channel blockade and to increases in heart rate: implications for gene-specific therapy. Circulation 1995; 92:3381-6.
138. Rosero SZ, Zareba W, Robinson JL, Moss AJ. Gene-specific therapy for long QT syndrome: QT shortening with lidocaineand tocainide in patients with mutation of the sodium-channel gene. Ann Noninvasive Electrocardiol 1997; 2:274-8.
139. Chezalviel-Guilbert F, Davy JM, Poirier JM, Weissenburger J. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. J Am Coll Cardiol 1995; 26:787-92.
140. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a population of young adults : echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995; 92:785-9.
141. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336:775-85.
142. Poetter K, Jiang H, Hassanzadeh S, et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nature Genet 1997; 13:63-9.
143. Kimura A, Harada H, Park J-E, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nature Genet 1997; 16:379-82.
144. O'Byrne S, Caulfield M. Genetics of hypertension. Therapeutics implications. Drugs 1998; 56:203-14.
145. Ferrari P. Pharmacogenomics: a new approach to individual therapy of hypertension? Curr Opin Nephrol Hypertens 1998; 7:217-22.
146. Yen TT, Yu P, Roeder H, Willard PW. A genetic study of hypertension in Okamoto-Aoki spontaneously hypertensive rats. Heredity 1974; 33:309-16.
147. Junemaitre X, Soubrier F, Kotelevtsen Y, Litton RP, Williams CS, Charru A, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71:169-80.
148. Soubrier F, Lathrop GM. The genetic basis of hypertension. Curr Opin Nephrol Hypertens 1995; 4:177-81.
149. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966; 95:1109-19.
150. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11beta-hydroxylase/aldosterone synthase gene causes glucocoticoid-remediable aldosterism and human hypertension. Nature 1992; 355:262-5.
151. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the β-subunit of the epithelial sodium channel. Cell 1994; 79:407-14.
152. Hansson JH, Nelson-Williams C, Suzuki H, Schild L, Shimkets R, Lu Y, et al. Hypertension caused by a truncated epithelial sodium channel γ-subunit: genetic heterogeneity of Liddle syndrome. Nature Genet 1995; 11:76-82.
153. O'Donnell CJ, Lindpaintner K, Larson MG, Rao VS, Ordovas JM, Schaefer EJ, et al. Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 1998; 97:1766-72.
154. Bianchi G, Tripodi G, Casari G, Salardi S, Barber BR, Garcia R, Leoni P, Torielli L, Cusi D, Ferrandi M, Pinna LA, Baralle FE, Ferrari P. Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci USA 1994; 91:3999-4003.
155. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, Glorioso N, Lanzani C, Manunta P, Righetti M, Rivera R, Stella P,. Troffa C, Zagato L, Bianchi G. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349: 1353-7.
156. Schunkert H, Hense H-W, Gimenez-Roqueplo A, et al. The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort. Hypertension 1997; 29:628-33.
157. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JEC, Brown MJ. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995; 13:1602-9.
158. Laragh JH, Lamport B, Sealey J, Alderman MH. Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension 1988; 12:223-6.
159. Davies JL, Kawaguchi Y, Bennett ST, Copeman JB, Cordell HJ, Protchard LE, Reed PW, Gough SCL, Jenkins SC, Palmer SM, Balfour KM, Rowe BR, Farrall M, Barnett AH, Bain SC, Todd JA. A genome-wide search for human type 1 diabetes susceptibility genes. Nature 1994; 371:130-6.
160. Baisch JM, Weeks T, Giles R, Hoover M, Stastny P, Capra JD. Analysis of HLA-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus. N Engl J Med 1990; 322: 1836-41.
161. Fava D, Gardner S, Pyke D, Leslie RDG. Evidence that the age at diagnosis of IDDM is genetically determined. Diabetes Care 1998; 21:925-9.
162. Fajans SS. Maturity-onset diabetes of the young (MODY). Diabetes Metab Rev 1989; 5:579-606.
163. Awata T, Kurihara S, Kikuchi C, Takai S-I, Inoue I, Ishii C, Takahashi K, Negishi K, Yoshida Y, Hagura R, Kanazawa Y, Katayama S. Evidence for association between the class 1 subset of the insulin gene minisatellite (IDDM 2 locus) and IDDM in the NIDDM. Diabetes 1997; 46:1725-32.
164. Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 1997; 46:1725-32.
165. Vionnet N, Stoffel M, TakedaJ, Yasuda K, Bell GI, Zouali H, Lesage S, Velho G, Iris F, Passa P, Froguel P, Cohen D. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature 1992; 356:721-2.
166. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, Southam L, Cox RD, Lathrop GM, Boriraj VV, Chen X, Cox NJ, Oda Y, Yano H, LeBeau MM, Yamada S, Nishigori H, Takeda J, Fajans SS, Hattersley AT, Iwasaki N, Hansen T, Pedersen O, Polonsky KS, Turner RC, Velho G, Chevre J-C, Froguel P, Cell GI. Mutations in the hepatocyte nuclear factor-1 alpha gene in maturity-onset diabetes of the young (MODY3). Nature 1996; 384:455-8.
167. Froguel P, Zouali H, Vionnet N, Velho G, Vaxillaire M, Sun F, Lesage S, Stoffel M, Takeda J, Passa P, Permutt A, Beckmann JS, Bell GI, Cohen D. Familial hyperglycemia due to mutations in glucokinase: definition of a subtype of diabetes mellitus. N Engl J Med 1993; 328:697-702.
168. Hani EH, Stoffers DA, Chevre J-C, Durand E, Stanojevic V, Dina C, Habener JF, Froguel P. Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. J Clin Invest 1999; 104:R41-8.
169. Shaw JTE, Lovelock PK, Kesting JB, Cardinal J, Duffy D, Wainwright B. Novel susceptibility gene for late-onset NIDDM is localized to human chromosome 12q. Diabetes 1998; 47:1793-6.
170. Wallace DC. Diseases of the mtDNA. Ann Rev Biochem 1992; 61:1175-212.
171. Lestienne P. Mitochondrial DNA mutations in human diseases: A review. Biochimie 1992; 74:123-30.
172. Isshiki G. Impaired glucose tolerance in the young. Nippon Rinsho 1997; 54:2766-72.
173. Suzuki Y, Tsukuda K, Atsumi Y, Goto Y, Hosokawa K, Asahina T, Nonaka I, Matsuoka K, Oka Y. Clinical picture of a case of diabetes with mitochondrial tRNA mutation at position 3271. Diabetes Care 1996; 19:1304-5.
174. Oka Y, Katagiri H, Ishihara H, Asano T, Kobayashi T, Kikuchi M. β-cell loss and glucose-induced signaling defects in diabetes mellitus caused by mitochondrial tRNA(Leu(UUR)) gene mutation. Diabet Med 1996; 13:S98-102.
175. Rotig A, Bessis JL, Romero N, Cormier V, Saudubray JM, Narcy P, Lenoir G, Rustin P, Munnich A. Maternally inherited duplication of the mitochondrial genome in a syndrome of proximal tubulopathy, diabetes mellitus, and cerebellar ataxia. Am J Hum Genet 1992; 50:364-70.
176. Anderson C, Herrnstadt C, Miller C, Olefsky J, Davis R. Mutations in mitochondrial ATPase 8 gene are associated with NIDDM. Diabetes 1997; 46:174A.
177. Berdanier CD. Diet can influence mitochondrial respiration in genetically diabetic BHE/Cdb rats: A review. Res Trends Endocrinol 1993; 12:103-15.
178. Berdanier CD. Noninsulin-dependent diabetes in the non-obeses BHE/Cdb rat. In : Shafrir E, ed. Recent advances in animal diabetes. London, Smith Gordon Publishers, 1994:231-46.
179. Allison DB, Kaprio J, Korkeila M, Koskenvuo M, Neale MC, Hayakawa K. The heritability of body mass index among an international sample of monozygotic twins reared apart. Int J Obesity Relat Metab Disord 1996; 20:501-6.
180. Comuzzie AG, Blangero J, Mahaney MC, Haffner SM, Mitchell BD, Stern MP,. MacCluer JW. Genetic and environmental correlations among hormone levels and measures of body fat accumulation and topography. J Clin Endocrinol Metabol 1996; 81:597-600.
181. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women - direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996; 45:633-8.
182. Rissanen P, Hamalainen P, Vanninen E, Tenhuneneskelinen M, Uusitupa M. Relationship of metabolic variables to abdominal adiposity measured by different anthropometric measurements and dual-energy x-ray absorptiometry in obese middle-aged women. Int J Obesity 1997; 21:367-71.
183. Zamboni M, Armellini F, Harris T, Turcato E, Micciolo R, Berganoardreis IA, et al. Effects of age on body fat distribution and cardiovascular risk factors in women. Am J Clin Nutr 1997; 66:111-15.
184. Whitiker R, Wright J, Pepe M, Seidel K, Dietz W. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med 1977; 337:869-73.
185. Tominaga K, Kurata JH, Chen YK, Fujimoto E, Miyagawa S, Abe I, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci 1995; 40:2002-9.
186. Brambilla P, Manzoni P, Sironi S, Simone P, Del Maschio A, di Natale B, et al. Peripheral and abdominal adiposity in childhood obesity. Int J Obes Relat Metab Disord 1994; 18:795-800.
187. Caprio S, Hyman LD, McCarthy S, Lange R, Bronson M, Tamborlane WV. Fat distribution and cardiovascular risk factors in obese adolescent girls - importance of the intraabdominal fat depot. Am J Clin Nutr 1996; 64:12-17.
188. Kortelainen ML. Association between cardiac pathology and fat tissue distribution in an autopsy series of men without premortem evidence of cardiovascular disease. Int J Obesity 1996; 20:245-52.
189. Vohl MC, Tchernof A, Dionne FT, Moorjani S, Prodhomme D, Bouchard C, et al. The apob-100 gene ecori polymorphism influences the relationship between features of the insulin resistance syndrome and the hyper-apob and dense Idl phenotype in men. Diabetes 1996; 45:1405-11.
190. Hokanson JE. Lipoprotein lipase gene variants and risk of coronary disease - a quantitative analysis of population-based studies (review). Int J Clin Lab Res 1997; 27:24-34.
191. Buemann B, Vohl MC, Chagnon M, Chagnon YC, Gagnon J, Perusse L, et al. Abdominal visceral fat is associated with a bcli restriction fragment length polymorphism at the glucocorticoid receptor gene locus. Obesity Res 1997; 5:186-92.
192. Yamada K, Yuan X, Ishiyama S, Koyama K, Ichikawa F, Koyanagi A, et al. Association between ala54the substitution of the fatty acid-binding protein 2 gene with insulin resistance and intra-abdominal fat thickness in Japanese men. Diabetologia 1997; 40:706-10.
193. Ronnemaa T, Karonen SL, Rissanen A, Koskenvuo M, Koivisto VA. Relationship between plasma leptin levels and measures of body fat in identical twins discordant for obesity. Ann Int Med 1997; 126:26-31.
194. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997; 385:165-8.
195. Frankish HM, Dryden S, Hopkins D, Wang Q, Williams G. Neuropeptide Y, the hypothalamus, and diabetes: insights into the central control of metabolism. Peptides 1995; 16(4):757-71.
196. Smith FJ, Campfield LA, Moschera JA, Bailon PS, Burn P. Feeding inhibition by neuropeptide Y [letter]. Nature 1996; 382:307.
197. Wang Z, Ren Ming Wang, Owji AA, Smith DM, Ghatei MA, Bloom SR. Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 1995; 95:417-21.
198. Friedman JM. The alphabet of weight control. Nature 1997; 385:119-20.
199. Bischoff A, Michel MC. Emerging functions for neuropeptide Y5 receptors. TIPS 1999; 20:104-6.
200. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA-1. Science 1994; 266:66-71.
201. Volgelstein B, Kinzler KW. Has the breast cancer gene been found? Cell 1994; 79:1-3.
202. Caldas C. Science, medicine, and the future. Molecular assessment of cancer. Br Med J 1998; 316:1360-3.
203. Valgardsdottir R, Tryggvadottir L, Steinarsdottir M, Olafsdottir K, Jonasdottir S, Jonasson JG, Ogmundsdottir HM, Eyfjord JE. Cenomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. APMIS 1997; 105:121-30.
204. Pharoah PDP, Day NE, Caldas C. Somatic mutations in the P53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999; 88:1968-73.
205. Jardines L, Weiss M, Fowble B, Greene M. Neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 1993; 61:268-82.
206. Schlessinger J. Regulation of cell growth by the EGF receptor. In: Kahn P, Graf T, eds. Oncogenes and Growth control. Heidelberg, Springer, 1986:77-84.
207. Delarue J, Friedman S, Mouriesse H, May-Levin F, Sancho-Garnier H, Contesso G. Epidermal growth factor receptor in human breast cancers. Correlation with estrogen and progesterone receptors. Breast Cancer Res Treat 1988; 11:173-8.
208. Akiyama T, Sudo C, Ogawara U, Toyoshima T, Yamamoto T. The product of the human c-erbB-2 gene: a 185 kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232:1644-6.
209. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA. The new oncogene: An erb-B related gene coding a 185, 000-Mr tumor antigen. Nature 1984; 312:513-16.
210. Muss HB, Thor AD, Berry DA, KuteT, Liu ET, Koerner F., Cirrincione CT, Budman DR, Wood WC, Barcos M, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330:1260-6.
211. Eissa S, Amina El-Chaich K, Salah N, Mohammed MK. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer. Anticancer Res 1997; 17:1417-24.
212. Wright C, Nicholson S, Angus B, Sainsbury JRC, Farndon J, Cairns J, Harris AL, Home CHW. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65:118-21.
213. De Potter CR, Schelflhout AM. The neu protein and breast cancer. Virchows Arch 1995; 426: 107-15.
214. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in ataxia-telangiectasia families. N Engl J Med 1987; 316:1289-94.
215. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991; 325:1831-6.
216. Gottlieb S. Drug to prevent breast cancer near approval. Br Med J 1998; 317:697.
217. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on february 20, 1996. J Clin Oncol 1996; 14:1730-6.
218. Raynaud SD, Baens M, Grosgeorge J, Rodgers K, Reid CDL, Dainton M, Dyer M, Fuzibet JG, Gratecos N, Taillan B, Ayraud N, Marynen P. Fluorescence in situ hybridization analysis of t(3; 12) (q26;p13): A recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes. Blood 1996; 88:682-9.
219. Schaller G, Bangemann N, Becker CH, Buhler H, Opri F, Weitzel HK. Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein. J Cancer Res Clin Oncol 1999; 125:520-4.
220. O'Regan R, Jordan VC. Update on tamoxifen, raloxifene, and breast cancer. Int Med 1999; 20:8-19.
221. Bookstein R, Demers W, Gregory R, Maneval D, Park J, Wills K. p53 Gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer. Semin Oncol 1996; 23:66-77.
222. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM. Science 1991; 254:713-16.
223. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256:1550-2.
224. Fricker J. Hepatocellular carcinoma and p53 gene therapy. Mol Med Today 1996; September:361.
225. Qin X-Q, Tao N, Dergay A, Moy P, Fawell S, Davis A, Wilson JM, Barsoum J. Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA 1998; 95:14411-16.
226. D'Amore PA. Mechanisms of endothelial growth control. Am J Resp Cell Mol Biol 1992; 6:1-8.
227. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995; 92:4562-6.
228. Norton HM, Anderson D, Hernandez P, Barnhart KM, Norman JA, Parker SE. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding Interferon α. Proc Natl Acad Sci USA 1999; 96:1553-8.
229. Alemany R, Gomez-Manzano C, Balague C, Yung WKA, Curiel DT, Kyritsis AP, Fueyo J. Gene therapy for gliomas: Molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 1999; 252:1-12.
230. Stephenson J. Human genome studies expected to revolutionize cancer classification. JAMA 1999; 282:927-8.
231. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 1999; 286:531-7.
232. Knoppers BM, Chadwick R. The Human Genome Project: Under an international ethical microscope. Science 1994; 265:2035-6.
233. Reilly PR, Boshar MF, Holtzman SH. Ethical issues in genetic research: disclosure and informed consent. Nature Genet 1997; 15:16-20.
234. Bankowski Z, Capron AM, eds. Proceedings of the 24th CIOMS Round Table Conference. The Inuyama Declaration. Geneva, CIOMS, 1993:1-3.
235. Council of Europe. Recommendation No. R (92) 3 of the Committee of Ministers to Member States on Genetic Testing and Screening for Health Care Purposes. Int Digest Health Legis 1992; 43:284.
236. Swiss Academy of Medical Sciences. Medical-Ethical Guidelines for Genetic Investigations in Humans (Directives médico-Ethiques concernant les examens génétiques sur l'homme. Bull Med Suisses 1993; 74(no. 38):1454.
237. Morton NE. Hippocratic or hypocritic: birth pangs of an ethical code. Nature Genet 1998; 18:18.
238. Mao X. Chinese geneticists' views of ethical issues in genetic testing and screening: evidence for eugenics in China. Am J Hum Genet 1998; 63:688-95.
239. Tvrdik T, Marcus S, Hou SM, Fait S, Noori P, Podlutskaja N, Hanefeld F, Stromme P, Lambert B. Molecular characterization of two deletion events involving Alusequences, one novel base substitution and two tentative hotspot mutations in the hypoxanthine phosphoribosyltransferase (HPRT) gene in five patients with Lesch-Nyhan syndrome. Hum Genet 1998; 103:311-18.
240. Yeh J, Zheng S, Howard BD. Impaired differentiation of HPRT-deficient dopaminergic neurons: a possible mechanism underlying neuronal dysfunction in Lesch-Nyhan syndrome. J Neurosci Res 1998; 53:78-85.
241. Carlson CG. The dystrophinopathies: an alternative to the structural hypothesis. Neurobiol Dis 1998; 5:3-15.
242. Hattori N, Yoshino H, Tanaka M, Suzuki H, Mizuno Y. Genotype in the 24-kDa subunit gene (NDUFV2) of mitochondrial complex I and susceptibility to Parkinson disease. Genomics 1998; 49:52-8.
243. Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2 + channel gene CACNL1A4. Cell 1996; 87:543-52.
244. Kotze MJ, Peeters AV, Loubser O, Theart L, du Plessis L, Hayes VM, de Jong G, de Villiers JN, Lombard CJ, Hansen PS, Raal FJ. Familial hypercholesterolemia: potential diagnostic value of mutation screening in a pediatric population of South Africa. Clin Genet 1998; 54:74-8.
245. Bradford LD, Kirlin WG. Polymorphism of CYP2D6 in black populations: implications for psychopharmacology. Int J Neuropsychopharmacol 1998; 1:173-85.
246. Nowak MP, Sellers EM, Tyndale RF. Canadian Native Indians exhibit unique CYPA6 and CYP2C19 mutant allele frequencies. Clin Pharmacol Therapeut 1998; 64:378-83.
247. Velho G, Froguel P. Genetic, metabolic and clinical characteristics of maturity onset diabetics of the young. Eur J Endocrinol 1998; 138:233-9.
248. Cuatrecasas G, Granada ML, Formiguera X, Rull M, Alastrue A, Remesar X, Alemany M, Foz M. Increased leptin production in vivo and insulin cleavage by the omental adipose tissue of morbidly obese patients. Clin Endocrinol 1998; 48:181-5.
249. Miedzybrodzka Z, Hattersley AT, Ellard S, Pearson D, De Silva D, Harvey R, Haites N. Non-penetrance in a MODY 3 family with a mutation in the hepatic nuclear factor 1 alpha gene: Implications for predictive testing. Eur J Hum Genet 1999; 7:729-32.
250. Suaud L, Hemimou Y, Formstecher P, Laine B, Functional study of the E276Q mutant hepatocyte nuclear factor-4alpha found in type 1 maturity-onset diabetes of the young: Impaired synergy with chicken ovalbumin upstream promoter transcription factor II on the hepatocyte nuclear factor-1 promoter. Diabetes 1999; 48:1162-7.
251. Majer M, Mott DM, Mochizuki H, Rowles JC, Pedersen O, Knowler WC, Bogardus C, Prochazka M. Association of the glycogen synthase locus on 19q13 with NIDDM in Pima Indians. Diabetologia 1996; 39:314-21.
252. Koike G, Van Vooren P, Shiozawa M, Galli J, Li L-S, Glaser A, Balasubramanyam A, Brown LJ, Luthman H, Szpirer C, MacDonald MJ, Jacob HJ. Genetic mapping and chromosome localization of the rat mitochondrial glycerol-3-phosphate dehydrogenase gene, a candidate for non-insulin-dependent diabetes mellitus. Genomics 1996; 38:96-9.
253. Huang C-N, Lee K-C, Wu H-P, Tai T-Y, Lin BJ, Chuang L-M. Screening for the Gly40Ser mutation in the glucagon receptor gene among patients with type 2 diabetes or essential hypertension in Taiwan. Pancreas 1999; 18:151-5.
254. Vionnet N, Hani EH, Lesage S, Philippi A, Hager J, Varret M, Stoffel M, Tanizawa Y, Chiu KC, Glaser B, Permutt MA, Passa P, Demenais F, Froguel P. Genetics of NIDDM in France: Studies with 19 candidate genes in affected sib pairs. Diabetes 1997; 46:1062-8.
255. Le Marchand-Brustel Y. Molecular mechanisms of insulin action in normal and insulin-resistant states. Exp Clin Endocrinol Diabetes 1999; 107:126-32.